Drug Profile


Alternative Names: JK 8792; Prosynap; R 87926

Latest Information Update: 03 Apr 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Janssen L.P.
  • Developer Janssen Pharmaceutical KK
  • Class Anti-ischaemics; Neuroprotectants; Piperidines; Small molecules; Thiazoles
  • Mechanism of Action Glutamate receptor antagonists; Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 03 Apr 2001 A study has been added to the therapeutic trials section
  • 23 Mar 1999 Discontinued-I for Stroke in Japan (Unknown route)
  • 23 Mar 1999 Discontinued-III for Stroke in Australia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top